The National Institute for Health and Care Excellence has expanded the treatment scope of Bayer’s Xofigo so that prostate cancer patients not suitable for chemotherapy can now also access the therapy on the NHS.
News
Industry-charity group to explore epigenetics in respiratory disease
AstraZeneca, MRC Technology and Asthma UK and the British Lung Foundation have joined forces to investigate the link between epigenetics and respiratory disease.
FDA OKs paediatric use of Amgen’s Blincyto
US regulators have issued an accelerated approval for use of Amgen’s immunotherapy Blincyto to treat paediatric patients with a rare form of leukaemia.
Pfizer’s Xalkori cleared for ROS1-positive lung cancer
The European Commission has widened the scope of Pfizer’s Xalkori to include the treatment of adults with ROS1-positive advanced non-small-cell lung cancer.
US expands use of Novartis/Genmab’s Arzerra
US regulators have expanded the approved uses of Novartis/Genmab’s Arzerra so that the biologic can now be used alongside fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukaemia.
Junior doctors plan five day strike
Hospitals in England are having to prepare for five days of strike action after junior doctors switched up a gear their campaign against the new working contract.
Google DeepMind, UCLH link for AI-based cancer treatment
Google’s artificial intelligence unit DeepMind and University College London Hospitals Foundation Trust have linked in under a medical research partnership aiming to develop pioneering technology able to automatically differentiate between cancerous and healthy tissues on patient scans.
University sues Gilead for patent infringement
The University of Minnesota has filed a lawsuit against Gilead Sciences claiming that the drugmaker’s hepatitis C drugs violate its intellectual property.
CR UK launches pancreatic cancer trial
Cancer Research UK has initiated a first-of-its-kind clinical trial to exploring whether pancreatic cancer cells can be made make more responsive to chemotherapy and radiotherapy.
Community pharmacy unveils its vision for the future
Pharmacy chiefs have published their vision for the future of community pharmacy in the UK, laying out a new roadmap to radically enhance and expand personalised care, support and wellbeing services provided by the sector.
Flutiform fails to hit targets in COPD trial
UK group Vectura saw its shares drop 10 percent after partner Munipharma reported that respiratory drug flutiform failed to hit targets in a late-stage trial involving patients with chronic obstructive pulmonary disease.
FDA green light for Sandoz’ Enbrel biosimilar
The US Food and Drug Administration has approved Sandoz’ biosimilar of Amgen’s blockbuster Enbrel.
Amgen’s Prolia shows promise in glucocorticoid osteoporosis
Top-line data from a late-stage trial of Amgen’s Prolia in osteoporosis patients receiving glucocorticoid therapy show that all primary and secondary targets being investigated were met.
Praluent slashes need for apheresis treatment
Sanofi/Regeneron’s cholesterol buster Praluent reduced the need for apheresis treatment in patients with very high cholesterol by 75 percent versus a placebo, show findings from the Phase III ODYSSEY ESCAPE trial.
UK’s annual asthma bill tops £1 billion
Asthma kills at least three people a day and costs the UK health service at least £1.1 billion a year, according to findings from what researchers are calling the most comprehensive study of the condition in the country to date.
